Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HYPD NASDAQ:LIAN NASDAQ:PHXM NASDAQ:RYZB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHYPDHyperion DeFi$12.88-18.8%$6.40$0.85▼$124.80$37.09M2.472.30 million shs1.04 million shsLIANLianBio$0.06+22.2%$0.35$0.27▼$4.99$5.94M0.231.04 million shs420,220 shsPHXMPHAXIAM Therapeutics$3.10$3.10$2.50▼$13.00$10.58M2.352,472 shsN/ARYZBRayzeBio$62.49$62.47$17.95▼$62.51$3.74BN/A553,592 shsN/AThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHYPDHyperion DeFi-0.69%+25.97%+127.55%+1,368.52%-83.88%LIANLianBio+22.22%-86.90%-85.51%-72.50%-81.67%PHXMPHAXIAM Therapeutics0.00%0.00%0.00%0.00%0.00%RYZBRayzeBio0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHYPDHyperion DeFi0.9438 of 5 stars1.05.00.00.02.90.00.6LIANLianBioN/AN/AN/AN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ARYZBRayzeBioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHYPDHyperion DeFi 2.00Hold$2.00-84.47% DownsideLIANLianBio 0.00N/AN/AN/APHXMPHAXIAM Therapeutics 0.00N/AN/AN/ARYZBRayzeBio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHYPDHyperion DeFi$60K618.24N/AN/A($695.52) per share-0.02LIANLianBioN/AN/AN/AN/A$2.71 per shareN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/A$7.98 per shareN/ARYZBRayzeBioN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHYPDHyperion DeFi-$49.82M-$58.40N/AN/AN/A-62,238.41%N/A-316.90%8/11/2025 (Estimated)LIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/APHXMPHAXIAM Therapeutics-$240KN/A0.00∞N/AN/AN/AN/AN/ARYZBRayzeBio-$68.60MN/A0.00N/AN/AN/AN/AN/AN/ALatest RYZB, LIAN, HYPD, and PHXM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025HYPDHyperion DeFi-$7.20-$1.59+$5.61-$1.59$1.60 million$1.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHYPDHyperion DeFiN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/APHXMPHAXIAM TherapeuticsN/AN/AN/AN/AN/ARYZBRayzeBioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHYPDHyperion DeFiN/A0.340.34LIANLianBioN/A10.0610.06PHXMPHAXIAM Therapeutics0.231.78N/ARYZBRayzeBioN/A31.8531.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHYPDHyperion DeFi25.84%LIANLianBio74.85%PHXMPHAXIAM Therapeutics0.40%RYZBRayzeBioN/AInsider OwnershipCompanyInsider OwnershipHYPDHyperion DeFi7.10%LIANLianBio7.59%PHXMPHAXIAM Therapeutics1.94%RYZBRayzeBioN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHYPDHyperion DeFi402.88 million2.68 millionOptionableLIANLianBio110108.06 million99.86 millionNot OptionablePHXMPHAXIAM Therapeutics493.41 million3.35 millionNo DataRYZBRayzeBio8859.92 millionN/AOptionableRYZB, LIAN, HYPD, and PHXM HeadlinesRecent News About These CompaniesDouble IPOs headline this week's biotech financingsMarch 23, 2025 | pharmaphorum.comPEsports Entertainment (OTC:GMBL) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comNextPlay Technologies (OTC:NXTP) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comLeddarTech Holdings (NASDAQ:LDTC) Stock Quotes, Forecast and News SummaryOctober 3, 2024 | benzinga.comBMS strikes again, with $4.1bn RayzeBio takeover bidAugust 2, 2024 | pharmaphorum.comPGetting In on This "Macro-Trend"May 10, 2024 | nasdaq.comAndreas Halvorsen's Firm Sells Out of RayzeBio IncFebruary 28, 2024 | finance.yahoo.comRYZB Aug 2024 35.000 putFebruary 27, 2024 | finance.yahoo.comRYZB May 2024 55.000 putFebruary 27, 2024 | finance.yahoo.comBristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical PlatformFebruary 26, 2024 | businesswire.comBMY Mar 2024 54.000 putFebruary 25, 2024 | ca.finance.yahoo.comBMY Apr 2024 43.000 putFebruary 24, 2024 | finance.yahoo.comBMY Mar 2024 48.000 callFebruary 24, 2024 | finance.yahoo.comBMY Mar 2024 47.000 putFebruary 24, 2024 | finance.yahoo.comBMY Mar 2024 43.000 putFebruary 24, 2024 | finance.yahoo.comBristol Myers Wraps RayzeBio Tender Offer with 86% of SharesFebruary 23, 2024 | marketwatch.comBristol Myers Squibb Announces Expiration of RayzeBio Tender OfferFebruary 23, 2024 | businesswire.comRayzeBio Stock (NASDAQ:RYZB), Quotes and News SummaryFebruary 22, 2024 | benzinga.comRYZB Feb 2024 65.000 callFebruary 18, 2024 | finance.yahoo.comBMY Feb 2024 37.000 putFebruary 13, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRYZB, LIAN, HYPD, and PHXM Company DescriptionsHyperion DeFi NASDAQ:HYPD$12.88 -2.98 (-18.79%) As of 04:00 PM EasternEyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.LianBio NASDAQ:LIAN$0.06 +0.01 (+22.22%) As of 07/16/2025LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.PHAXIAM Therapeutics NASDAQ:PHXM$3.10 0.00 (0.00%) As of 07/16/2025PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.RayzeBio NASDAQ:RYZBRayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California. As of February 26, 2024, RayzeBio, Inc. operates as a subsidiary of Bristol-Myers Squibb Company. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield How Goldman Sachs Earnings Help You Strategize Your Portfolio Is Amazon Really the Best Forever Stock for Your Portfolio? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
